首页> 美国卫生研究院文献>Cold Spring Harbor Molecular Case Studies >Whole-genome and transcriptome profiling of a metastatic thyroid-like follicular renal cell carcinoma
【2h】

Whole-genome and transcriptome profiling of a metastatic thyroid-like follicular renal cell carcinoma

机译:转移性甲状腺样滤泡性肾细胞癌的全基因组和转录组分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Thyroid-like follicular renal cell carcinoma (TLFRCC) is a rare cancer with few reports of metastatic disease. Little is known regarding genomic characteristics and therapeutic targets. We present the clinical, pathologic, genomic, and transcriptomic analyses of a case of a 27-yr-old male with TLFRCC who presented initially with bone metastases of unknown primary. Genomic DNA from peripheral blood and metastatic tumor samples were sequenced. A transcriptome of 280 million sequence reads was generated from the same tumor sample. Tumor somatic expression profiles were analyzed to detect aberrant expression. Genomic and transcriptomic data sets were integrated to reveal dysregulation in pathways and identify potential therapeutic targets. Integrative genomic analysis with The Cancer Genome Atlas (TCGA) data set revealed the following outliers in gene expression profiles: CDK6 (81st percentile), MYC (99th percentile), AR (100th percentile), PDGFRA and PDGFRB (99th and 100th percentiles, respectively), and MAP2K2 (86th percentile). The patient received first-line sunitinib to target PDGFRA and PDGFRB and had stable disease for >6 mo, followed by nivolumab upon progression. To the authors’ knowledge, this is the first reported case of comprehensive somatic genomic analyses in a patient with metastatic TLFRCC. Somatic analyses provided molecular confirmation of the primary site of cancer and potential therapeutic strategies in a rare disease with little evidence of efficacy on systemic therapy.
机译:甲状腺样滤泡性肾细胞癌(TLFRCC)是一种罕见的癌症,很少有转移性疾病的报道。关于基因组特征和治疗目标知之甚少。我们介绍了一名27岁男性TLFRCC患者的临床,病理,基因组和转录组学分析,该患者最初出现未知原发性骨转移。对来自外周血和转移性肿瘤样品的基因组DNA进行测序。从相同的肿瘤样品中产生了2.8亿个序列读数的转录组。分析肿瘤的体细胞表达谱以检测异常表达。基因组和转录组数据集被整合以揭示通路中的失调并确定潜在的治疗靶标。与癌症基因组图谱(TCGA)数据集的整合基因组分析揭示了以下基因表达谱中的异常值:CDK6(第81个百分点),MYC(第99个百分点),AR(第100个百分点),PDGFRA和PDGFRB(分别为第99个和第100个百分点) )和MAP2K2(第86个百分点)。该患者接受一线舒尼替尼靶向PDGFRA和PDGFRB,病情稳定持续6个月以上,随后病情进展为nivolumab。据作者所知,这是首次报告转移性TLFRCC患者进行全面体细胞基因组分析的病例。体细胞分析提供了对癌症主要部位的分子确认以及罕见疾病中潜在的治疗策略,几乎没有全身疗法疗效的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号